Athersys (ATHX) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of Athersys (NASDAQ:ATHX) from a sell rating to a hold rating in a research report sent to investors on Wednesday.

A number of other equities analysts also recently weighed in on ATHX. Zacks Investment Research downgraded shares of Athersys from a buy rating to a sell rating in a research note on Wednesday, July 11th. Maxim Group reissued a buy rating and set a $6.00 target price on shares of Athersys in a research note on Tuesday, July 31st.

Shares of NASDAQ ATHX opened at $2.12 on Wednesday. Athersys has a twelve month low of $1.29 and a twelve month high of $3.09. The firm has a market cap of $299.34 million, a P/E ratio of -7.31 and a beta of -0.65.

Athersys (NASDAQ:ATHX) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter. Athersys had a negative net margin of 106.99% and a negative return on equity of 61.52%. The business had revenue of $19.39 million during the quarter, compared to the consensus estimate of $12.82 million. analysts expect that Athersys will post -0.21 EPS for the current fiscal year.

In other Athersys news, insider Laura K. Campbell sold 28,868 shares of Athersys stock in a transaction on Friday, August 10th. The shares were sold at an average price of $2.01, for a total value of $58,024.68. Following the completion of the sale, the insider now directly owns 590,424 shares of the company’s stock, valued at $1,186,752.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider William Lehmann, Jr. sold 15,000 shares of Athersys stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,200.00. Following the completion of the sale, the insider now directly owns 517,373 shares of the company’s stock, valued at $972,661.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,088 shares of company stock valued at $149,487. Insiders own 18.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in Athersys by 214.9% in the first quarter. JPMorgan Chase & Co. now owns 69,370 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 47,339 shares in the last quarter. Alps Advisors Inc. bought a new stake in Athersys in the second quarter valued at $394,000. Schwab Charles Investment Management Inc. increased its stake in Athersys by 50.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 84,600 shares in the last quarter. Renaissance Technologies LLC increased its stake in Athersys by 21.3% in the second quarter. Renaissance Technologies LLC now owns 439,900 shares of the biopharmaceutical company’s stock valued at $867,000 after purchasing an additional 77,100 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Athersys by 377.6% in the second quarter. Millennium Management LLC now owns 457,667 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 361,835 shares in the last quarter. 19.02% of the stock is owned by hedge funds and other institutional investors.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Story: Call Option

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply